FLT3 and acute myeloid leukemia: Gilteritinib is an ATP-competitive tyrosine multi-kinase inhibitor that has been approved for treating relapsed or refractory Fms-like tyrosine kinase 3 (FLT3)-positive acute myeloid leukemia (AML) (Pulte et al., 2021).